Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning?

C Jung, D Kmiec, L Koepke, F Zech, T Jacob… - Journal of …, 2022 - Am Soc Microbiol
Emerging strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show …

Approved antiviral drugs over the past 50 years

E De Clercq, G Li - Clinical microbiology reviews, 2016 - Am Soc Microbiol
Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs
categorized into 13 functional groups have been formally approved for the treatment of the …

[HTML][HTML] The paradox of HIV blood–brain barrier penetrance and antiretroviral drug delivery deficiencies

O Osborne, N Peyravian, M Nair, S Daunert… - Trends in …, 2020 - cell.com
HIV attacks the body's immune cells, frequently compromises the integrity of the blood–brain
barrier (BBB), and infects the CNS in the early stages of infection. Dysfunction of the BBB …

[HTML][HTML] Approved HIV reverse transcriptase inhibitors in the past decade

G Li, Y Wang, E De Clercq - Acta Pharmaceutica Sinica B, 2022 - Elsevier
HIV reverse transcriptase (RT) inhibitors are the important components of highly active
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …

Population genomics of intrapatient HIV-1 evolution

F Zanini, J Brodin, L Thebo, C Lanz, G Bratt, J Albert… - Elife, 2015 - elifesciences.org
Many microbial populations rapidly adapt to changing environments with multiple variants
competing for survival. To quantify such complex evolutionary dynamics in vivo, time …

HIV genome-wide protein associations: a review of 30 years of research

G Li, E De Clercq - Microbiology and Molecular Biology Reviews, 2016 - Am Soc Microbiol
The HIV genome encodes a small number of viral proteins (ie, 16), invariably establishing
cooperative associations among HIV proteins and between HIV and host proteins, to invade …

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

Y Wang, E De Clercq, G Li - Expert opinion on drug metabolism & …, 2019 - Taylor & Francis
Introduction: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are essential
components of highly active antiretroviral therapy against HIV-1 infections. Here, we provide …

[HTML][HTML] Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins

S Rebensburg, M Helfer, M Schneider… - Scientific reports, 2016 - nature.com
Novel therapeutic options are urgently needed to improve global treatment of virus
infections. Herbal products with confirmed clinical safety features are attractive starting …

In vivo mutation rates and the landscape of fitness costs of HIV-1

F Zanini, V Puller, J Brodin, J Albert, RA Neher - Virus evolution, 2017 - academic.oup.com
Mutation rates and fitness costs of deleterious mutations are difficult to measure in vivo but
essential for a quantitative understanding of evolution. Using whole genome deep …

HIV-1 protease, reverse transcriptase, and integrase variation

SY Rhee, K Sankaran, V Varghese, MA Winters… - Journal of …, 2016 - Am Soc Microbiol
ABSTRACT HIV-1 protease (PR), reverse transcriptase (RT), and integrase (IN) variability
presents a challenge to laboratories performing genotypic resistance testing. This challenge …